Search Results

Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).

• Authors : Sakaguchi H; Umeda K ...

Subjects: Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/adverse effects ; Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/therapeutic use ; Antigens, CD19*/Antigens, CD19*/Antigens, CD19*/metabolism

• Source: BMJ open [BMJ Open] 2023 Apr 17; Vol. 13 (4), pp. e070051. Date of Electronic Publication: 2023 Apr 17.Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Ensuring the Scientific Value and Feasibility of Clinical Trials: A Qualitative Interview Study.

• Authors : Morrell W; Multi-Regional Clinical Trials Center, Brigham & Women's Hospital and Harvard, Cambridge, MA, USA.; Gelinas L

Subjects: Clinical Trials Data Monitoring Committees* ; Research Design*; Humans

• Source: AJOB empirical bioethics [AJOB Empir Bioeth] 2023 Apr-Jun; Vol. 14 (2), pp. 99-110. Date of Electronic Publication: 2023 Jan 04.Publisher: Taylor & Francis Group, 2014- Country of Publication: United States NLM ID: 101631047 Publication Model: Print-Electronic Cited Medium:

Record details

Optimizing pharmaceutical management of clinical trials.

• Authors : Farhat A; Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Subjects: Pharmaceutical Preparations* ; Clinical Trials as Topic*; Humans

• Source: Annales pharmaceutiques francaises [Ann Pharm Fr] 2024 Mar; Vol. 82 (2), pp. 285-291. Date of Electronic Publication: 2023 Dec 28.Publisher: Elsevier Masson Editeur Country of Publication: France NLM ID: 2985176R Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Transforming clinical trials.

Subjects: *CLINICAL trials

• Source: New Scientist. 3/9/2024, Vol. 261 Issue 3481, p26-27. 2p. 3 Color Photographs.

Record details

Characterization of alopecia clinical trials: an analysis of trials registered on clinicaltrials.gov.

• Authors : Konisky H; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY, 10461, USA. .; Balazic E

Subjects: Alopecia*/Alopecia*/Alopecia*/diagnosis ; Alopecia*/Alopecia*/Alopecia*/therapy ; Clinical Trials as Topic*

• Source: Archives of dermatological research [Arch Dermatol Res] 2024 Apr 01; Vol. 316 (4), pp. 116. Date of Electronic Publication: 2024 Apr 01.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8000462 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-069X

Record details

Current usage of explainer animations in trials: a survey of the UKCRC registered clinical trial units in the UK.

• Authors : Barber VS; Oxford Clinical Trials Research Unit (OCTRU), University of Oxford, Oxford, UK. .; Calvert C

Subjects: Clinical Trials as Topic*; Humans ; Research Design

• Source: Trials [Trials] 2024 Mar 28; Vol. 25 (1), pp. 224. Date of Electronic Publication: 2024 Mar 28.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

Record details

TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.

• Authors : Smith KL; Sidney Kimmel Comprehensive Cancer Center, Women's Malignancies Disease Group, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Mead-Harvey C

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/therapy ; Pandemics* ; Clinical Trials as Topic*

• Source: Cancer medicine [Cancer Med] 2024 Mar; Vol. 13 (5), pp. e7090.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Quantifying Site Burden to Optimize Protocol Performance.

• Authors : Florez M; Tufts Center for the Study of Drug Development, Tufts School of Medicine, Boston, USA. .; Smith Z

Subjects: Clinical Trials as Topic*/Clinical Trials as Topic*/Clinical Trials as Topic*/standards; Humans ; Surveys and Questionnaires

• Source: Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2024 Mar; Vol. 58 (2), pp. 347-356. Date of Electronic Publication: 2024 Jan 08.Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101597411 Publication Model: Print-Electronic Cited Medium:

Record details

Speed up relief for long COVID through grassroots clinical trials.

• Authors : Jamoulle M; Louazon E; Antonacci T

Subjects: Post-Acute COVID-19 Syndrome*/Post-Acute COVID-19 Syndrome*/Post-Acute COVID-19 Syndrome*/therapy ; Clinical Trials as Topic*/Clinical Trials as Topic*/Clinical Trials as Topic*/methods ; Clinical Trials as Topic*/Clinical Trials as Topic*/Clinical Trials as Topic*/organization & administration

• Source: Nature [Nature] 2024 Feb; Vol. 626 (8001), pp. 954.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Move over, CRISPR: RNA-editing therapies pick up steam.

• Authors : Lenharo M

Subjects: Clinical Trials as Topic*/Clinical Trials as Topic*/Clinical Trials as Topic*/legislation & jurisprudence ; Clinical Trials as Topic*/Clinical Trials as Topic*/Clinical Trials as Topic*/standards ; CRISPR-Cas Systems*/CRISPR-Cas Systems*/CRISPR-Cas Systems*/genetics

• Source: Nature [Nature] 2024 Feb; Vol. 626 (8001), pp. 933-934.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print Cited Medium: Internet ISSN:

Record details